Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
155 hedge funds and large institutions have $1.25B invested in Esperion Therapeutics in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 51 increasing their positions, 47 reducing their positions, and 25 closing their positions.
9% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 47
4% more capital invested
Capital invested by funds: $1.21B → $1.25B (+$44.2M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
1% less funds holding
Funds holding: 156 → 155 (-1)
4% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 25
9.71% less ownership
Funds ownership: 115.22% → 105.51% (-9.7%)
77% less call options, than puts
Call options by funds: $34.7M | Put options by funds: $151M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Nova Scotia
Toronto,
Ontario, Canada
|
+$8.03M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$6.57M |
| 3 |
Man Group
London,
United Kingdom
|
+$5.53M |
| 4 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$4.59M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$22.5M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$20.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.8M |
| 4 |
State Street
Boston,
Massachusetts
|
-$15.1M |
| 5 |
VOYA Investment Management
Atlanta,
Georgia
|
-$13.2M |
ESPR Hedge Fund Activity: Q3 2018 in Review
155 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2018, worth a combined $1.25B — up 3.6% from $1.21B a quarter earlier.
Sellers outnumbered buyers: 25 funds closed out of ESPR and 24 opened new positions — a net loss of 1 holder — while 47 trimmed existing stakes and 51 added.
The largest buyer was Bank of Nova Scotia, adding an estimated $8.03M. The largest seller was PFM Health Sciences, cutting an estimated $22.5M.
- 155 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2018, down from 156 in Q2 2018.
- Funds reported $1.25B of Esperion Therapeutics stock for Q3 2018, up 3.6% quarter-over-quarter.
- 24 funds opened new Esperion Therapeutics positions in Q3 2018 and 25 closed out, a net change of -1 holder.
- The largest Esperion Therapeutics buyer in Q3 2018 was Bank of Nova Scotia, an estimated $8.03M added.
- The largest Esperion Therapeutics seller in Q3 2018 was PFM Health Sciences, an estimated $22.5M sold.
Based on aggregated 13F filings for Q3 2018.